UA79650C2 - Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy - Google Patents

Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy Download PDF

Info

Publication number
UA79650C2
UA79650C2 UAA200505318A UA2005005318A UA79650C2 UA 79650 C2 UA79650 C2 UA 79650C2 UA A200505318 A UAA200505318 A UA A200505318A UA 2005005318 A UA2005005318 A UA 2005005318A UA 79650 C2 UA79650 C2 UA 79650C2
Authority
UA
Ukraine
Prior art keywords
use according
docosahexaenoic acid
lipodystrophy
treatment
extract
Prior art date
Application number
UAA200505318A
Other languages
English (en)
Ukrainian (uk)
Inventor
Pedrol Juan Carlos Domingo
Pedrol Pere Domingo
Original Assignee
Proyecto Empresarial Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresarial Brudy Sl filed Critical Proyecto Empresarial Brudy Sl
Publication of UA79650C2 publication Critical patent/UA79650C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UAA200505318A 2002-12-05 2003-01-12 Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy UA79650C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200202963A ES2209658B1 (es) 2002-12-05 2002-12-05 Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
PCT/IB2003/005673 WO2004050077A1 (en) 2002-12-05 2003-12-01 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
UA79650C2 true UA79650C2 (en) 2007-07-10

Family

ID=32405973

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200505318A UA79650C2 (en) 2002-12-05 2003-01-12 Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy

Country Status (24)

Country Link
US (1) US8202906B2 (de)
EP (1) EP1585513B1 (de)
JP (1) JP2006511514A (de)
KR (1) KR100906086B1 (de)
CN (1) CN100355421C (de)
AT (1) ATE326959T1 (de)
AU (1) AU2003302679B2 (de)
BR (1) BR0316973A (de)
CA (1) CA2506993C (de)
CY (1) CY1105205T1 (de)
DE (1) DE60305534T2 (de)
DK (1) DK1585513T3 (de)
EA (1) EA009711B1 (de)
ES (2) ES2209658B1 (de)
IL (1) IL168766A (de)
IS (1) IS2384B (de)
MX (1) MXPA05005911A (de)
NO (1) NO20052960L (de)
NZ (1) NZ540262A (de)
PL (1) PL377563A1 (de)
PT (1) PT1585513E (de)
UA (1) UA79650C2 (de)
WO (1) WO2004050077A1 (de)
ZA (1) ZA200503872B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656934A1 (de) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Verwendung von physiologisch aktiven Fettsäuren zur Behandlung von Lipodystrophie
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5207342B2 (ja) * 2007-02-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN103372215B (zh) * 2008-01-03 2016-03-09 艾克斯-马赛大学 抗hiv治疗期间使用的组合物和方法
CN110339187B (zh) * 2019-07-30 2021-12-14 中国医学科学院病原生物学研究所 缓解寨卡病毒感染相关的新生儿小头症的药物
CN116585216A (zh) * 2022-05-16 2023-08-15 上海中翊日化有限公司 一种含有羟基频哪酮视黄酸酯(hpr)并降低光损伤及炎症的抗衰组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901048A1 (de) 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0923817A (ja) * 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
FR2749133A1 (fr) * 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CA2290885A1 (fr) * 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
DK1121928T3 (da) * 2000-01-31 2008-03-17 Haerting S A Sammensætninger indeholdende phytosterol- og policosanolestere af fedtsyrer til reduktion af niveauet af blodcholesterol og -triglycerider
JP2001314170A (ja) * 2000-05-09 2001-11-13 Toyo Shinyaku:Kk 麦若葉由来の素材を含む抗コレステロール食品
DK1157692T3 (da) * 2000-05-22 2006-02-06 Pro Aparts Investimentos E Con Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
ES2209658A1 (es) 2004-06-16
ZA200503872B (en) 2006-08-30
ES2209658B1 (es) 2005-10-01
IS7912A (is) 2005-06-23
US20060178436A1 (en) 2006-08-10
AU2003302679B2 (en) 2009-01-15
AU2003302679A1 (en) 2004-06-23
WO2004050077A1 (en) 2004-06-17
MXPA05005911A (es) 2005-08-29
EA009711B1 (ru) 2008-02-28
CA2506993A1 (en) 2004-06-17
CY1105205T1 (el) 2010-03-03
KR100906086B1 (ko) 2009-07-06
PT1585513E (pt) 2006-10-31
CA2506993C (en) 2010-04-13
NO20052960L (no) 2005-06-16
JP2006511514A (ja) 2006-04-06
BR0316973A (pt) 2005-10-25
NZ540262A (en) 2006-11-30
IS2384B (is) 2008-07-15
EP1585513B1 (de) 2006-05-24
EP1585513A1 (de) 2005-10-19
CN1720039A (zh) 2006-01-11
EA200500765A1 (ru) 2005-12-29
PL377563A1 (pl) 2006-02-06
ATE326959T1 (de) 2006-06-15
ES2265607T3 (es) 2007-02-16
DE60305534D1 (de) 2006-06-29
CN100355421C (zh) 2007-12-19
KR20050085313A (ko) 2005-08-29
US8202906B2 (en) 2012-06-19
IL168766A (en) 2009-11-18
DK1585513T3 (da) 2006-09-18
DE60305534T2 (de) 2007-05-16

Similar Documents

Publication Publication Date Title
NO326926B1 (no) Anvendelse av eikosapentaensyre og/eller stearidonsyre i fremstilling av medikamenter
SK286523B6 (sk) Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu
WO2004073706A1 (ja) リバビリン/インターフェロン併用療法の副作用軽減剤
UA79650C2 (en) Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy
TW200410683A (en) Medicament for preventing and/or treating peripheral neuropathies
AU2016402338A1 (en) Combinational compositions and methods of use thereof
JP5952556B2 (ja) 褥瘡治療剤
US20080161604A1 (en) Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
JP2024526939A5 (de)
JP5710150B2 (ja) 潜伏性感染疾患の再発抑制剤
US20200085774A1 (en) Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia
CN110013474A (zh) 非诺贝特的新用途以及针对新用途的药物
US20170296499A1 (en) Combinational compositions and methods of use thereof
EP1874288B1 (de) Acetyl l-carnitin zur vorbeugung schmerzhafter periphärer diabetischer neuropathie
JP2010090087A (ja) 潜伏性感染疾患の再発抑制剤
WO2025075519A1 (en) Preparation and its application in atopic dermatitis in children
AU2016390920A1 (en) New use of isoquinoline derivatives for diabetic wound healing
CN118453565A (zh) 癸酸单甘油酯在制备肥胖症治疗药物或功能食品中的应用
CN102416015A (zh) 一种含他汀类药物的组合物及其用途
RU2021111065A (ru) Композиции и способы с использованием по меньшей мере одного глицина или его производного, по меньшей мере одного n-ацетилцистеина или его производного и по меньшей мере одного никотинамидрибозида или предшественника nad+